4/23
07:04 am
omga
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting [Yahoo! Finance]
Low
Report
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting [Yahoo! Finance]
4/23
07:00 am
omga
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
Low
Report
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
4/17
05:02 pm
omga
CVAC, SBNY and CRMD are among after hour movers [Seeking Alpha]
Low
Report
CVAC, SBNY and CRMD are among after hour movers [Seeking Alpha]
4/17
11:40 am
omga
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
Low
Report
Omega Therapeutics (OMGA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now [Yahoo! Finance]
4/9
07:15 am
omga
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control [Yahoo! Finance]
Medium
Report
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control [Yahoo! Finance]
4/9
07:00 am
omga
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
Medium
Report
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
4/3
01:21 pm
omga
Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Omega Therapeutics (OMGA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
4/3
12:12 pm
omga
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $9.00 price target on the stock, down previously from $10.00.
Low
Report
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $9.00 price target on the stock, down previously from $10.00.
4/1
09:01 am
omga
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its price target lowered by analysts at Chardan Capital from $12.00 to $7.00. They now have a "buy" rating on the stock.
High
Report
Omega Therapeutics, Inc. (NASDAQ: OMGA) had its price target lowered by analysts at Chardan Capital from $12.00 to $7.00. They now have a "buy" rating on the stock.
3/31
06:36 am
omga
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' [Seeking Alpha]
Medium
Report
Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' [Seeking Alpha]
3/29
08:53 am
omga
We Think Omega Therapeutics (NASDAQ:OMGA) Needs To Drive Business Growth Carefully [Yahoo! Finance]
Medium
Report
We Think Omega Therapeutics (NASDAQ:OMGA) Needs To Drive Business Growth Carefully [Yahoo! Finance]
3/28
11:39 am
omga
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Omega Therapeutics, Inc. (OMGA) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
3/28
09:15 am
omga
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
Low
Report
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
3/6
07:12 am
omga
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
3/6
07:00 am
omga
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
Medium
Report
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024